Table 4.
Incremental cost-effectiveness ratios for each scenario.
| Scenario | Societal perspectivea |
Health system perspective |
Patient perspectivea |
|||
|---|---|---|---|---|---|---|
| Incremental cost per DALY averted | Incremental cost per death averted | Incremental cost per DALY averted | Incremental cost per death averted | Incremental cost per DALY averted | Incremental cost per death averted | |
| Status quo | Reference | Reference | Reference | Reference | Reference | Reference |
| Hospital scale up (without demand shift) | −$2154 | −$69,932 | $460 | $14,947 | −$2614 | −$84,878 |
| CHC scale up (without demand shift) | −$2307 | −$74,101 | $308 | $9888 | −$2614 | −$83,989 |
| Hospital and CHC scale up (without demand shift) | −$2286 | −$73,492 | $328 | $10,544 | −$2614 | −$84,036 |
| Hospital scale up (with demand shift) | −$2185 | −$70,118 | $417 | $13,386 | −$2602 | −$83,504 |
| CHC scale up (with demand shift) | −$2312 | −$74,257 | $301 | $9674 | −$2614 | −$83,932 |
| Hospital and CHC scale up (with demand shift) | −$2291 | −$73,643 | $323 | $10,379 | −$2614 | −$84,022 |
a
A negative sign indicates that economic costs decreased as a result of antivenom scale-up. Negative values therefore reflect net economic benefits per DALY/death averted.